Human clinical trials could begin as early as next year
A team of researchers at the University of Georgia’s Regenerative Bioscience Center and ArunA Biomedical, a UGA startup company, have developed a new treatment for stroke that reduces brain damage and accelerates the brain’s natural healing tendencies in animal models. They published their findings in the journal Translational Stroke Research.
The research team led by UGA professor Steven Stice and Nasrul Hoda of Augusta University created a treatment called AB126 using extracellular vesicles (EV), fluid-filled structures known as exosomes, which are generated from human neural stem cells.
Fully able to cloak itself within the bloodstream, this type of regenerative EV therapy appears to be the most promising in overcoming the limitations of many cell therapies—with the ability for exosomes to carry and deliver multiple doses—as well as the ability to store and administer treatment. Small in size, the tiny tubular shape of an exosome allows EV therapy to cross barriers that cells cannot.
“This is truly exciting evidence, because exosomes provide a stealth-like characteristic, invisible even to the body’s own defenses,” said Stice, Georgia Research Alliance Eminent Scholar and D.W. Brooks Distinguished Professor in the College of Agricultural and Environmental Sciences. “When packaged with therapeutics, these treatments can actually change cell progression and improve functional recovery.”
Following the administration of AB126, the researchers used MRI scans to measure brain atrophy rates in preclinical, age-matched stroke models, which showed an approximately 35 percent decrease in the size of injury and 50 percent reduction in brain tissue loss—something not observed acutely in previous studies of exosome treatment for stroke.
Outside of rodents, the results were replicated by Franklin West, associate professor of animal and dairy science, and fellow RBC members using a porcine model of stroke—the only one of its kind in the U.S.
Based on these pre-clinical results, ArunA Biomedical plans to begin human studies in 2019, said Stice, who is also chief scientific officer of ArunA Biomedical.
“Until now, we had very little evidence specific to neural exosome treatment and the ability to improve motor function,” said Stice. “Just days after stroke, we saw better mobility, improved balance and measurable behavioral benefits in treated animal models.”
Named as part of the ‘stroke belt’ region, Georgia continues to exceed the national average in stroke deaths, which is the third leading cause of death in the U.S., with more than 140,000 Americans dying each year, according to the Centers for Disease Control and Prevention.
ArunA recently unveiled advances to the company’s proprietary neural cell platform for the production of exosome manufacturing. Today, ArunA’s manufacturing process positions the company to produce AB126 exosomes at a scale to meet early clinical demand. The company has plans to expand this initiative beyond stroke for preclinical studies in epilepsy, traumatic brain and spinal cord injuries later this year.
The Latest on: Stroke treatment
via Google News
The Latest on: Stroke treatment
- Treatment of mental health issues neglected during stroke recoveryon November 23, 2020 at 10:21 pm
The health system is failing to recognize the importance of treating mental health issues in stroke recovery. Stroke attacks the brain, the human control center determining how we move, think, feel ...
- Smart ambulances and wearables offer route to speedier treatmentson November 23, 2020 at 7:33 pm
Service that improves treatment for patients on way to hospital to be introduced across UK after successful trial ...
- Targeting calcium overload could improve stroke outcomes, research suggestson November 23, 2020 at 6:35 am
Excessive calcium contributes to harmful inflammation in ischemic stroke, and targeting it may provide doctors with a new way to improve patient outcomes.
- Removing the Ishemic; Stroke Treatment Device Recalled - What You Need To Knowon November 20, 2020 at 1:16 pm
When this happens, parts of the device can be left inside the patient’s blood vessel. This can cause serious injuries, including additional blockage of the vessel, disability, and death. Accordingly, ...
- Dr. Roach: Is there a stroke link to Fosamax?on November 19, 2020 at 4:13 pm
The correlation between alendronate (Fosamax) and stroke has been studied, but the conclusions are far from clear ...
- Emergency treatment for devastating stroke to be tested in Memphison November 19, 2020 at 11:39 am
The University of Tennessee Health Science Center's Stroke Team is joining researchers from more than 100 hospitals worldwide to conduct a National Institutes of Health (NIH)-funded research study ...
- Global Stroke Treatment Drugs Market: 2020 Market Research with Size, Growth, Manufacturers, Segments and 2024 Forecasts Researchon November 19, 2020 at 10:36 am
Global “Stroke Treatment Drugs" Market 2024 Research Report provide in-depth study of the present state of the ...
- Blood Pressure Treatment Reduces Bleeding in ICHon November 19, 2020 at 8:33 am
Compared with standard treatment, intensive blood pressure lowering does not improve function but does appear to reduce hematoma growth, a new study suggests.
- Austin-Area St. David's HealthCare Sites Honored For Stroke Careon November 18, 2020 at 3:21 am
The four medical facilities were lauded by the American Heart Association/American Stroke Association for 'exceptional' care.
- St. David’s HealthCare Sites In WilCo Honored For Stroke Careon November 17, 2020 at 10:23 pm
Four Austin-area medical facilities were lauded by the American Heart Association/American Stroke Association for 'exceptional' care.
via Bing News